Showing results (71-80 of 280) with videos related to
Sort By:
Pageof 28
Haematologica|November 22, 2011
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromesSheila Weiss Smith, Masayo Sato, Steven D Gore, et al.Cancer|August 1, 2017
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trialsAmer M Zeidan, Maximilian Stahl, Mikkael A Sekeres, et al.Journal of Medicinal Chemistry|September 30, 2005
Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitorsSheeba Varghese, Deepak Gupta, Tiffany Baran, et al.The Journal of Biological Chemistry|April 23, 2014
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemiaJeremy D Waight, Debarati Banik, Elizabeth A Griffiths, et al.Leukemia Research|March 26, 2013
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelinesAmy J Davidoff, Sheila R Weiss, Maria R Baer, et al.Blood Reviews|March 13, 2016
Epigenetics: A primer for cliniciansBenjamin E Paluch, Abdul R Naqash, Zachary Brumberger, et al.Blood Cancer Discovery|November 15, 2021
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic MalignanciesAntoni Ribas, Madhav V Dhodapkar, Katie M Campbell, et al.Biomedical Chromatography : BMC|November 30, 2021
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclaxSusan C Scott, Nicole M Anders, Ping He, et al.Cancer|August 8, 2013
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromesAmer M Zeidan, Steven D Gore, Diane L McNally, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2010
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade, B Douglas Smith, Steven D Gore, et al.Pageof 28